PROLONG-II Study: Difference between revisions
No edit summary |
Rim Halaby (talk | contribs) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 24: | Line 24: | ||
|- | |- | ||
|} | |} | ||
<span style="font-size:85%">The previous information was derived from ClinicalTrials.gov on 09/ | <span style="font-size:85%">The previous information was derived from ClinicalTrials.gov on 09/25/2013 using the identification number NCT00266045</span> | ||
==Study Description== | ==Study Description== | ||
| Line 44: | Line 44: | ||
|} | |} | ||
<span style="font-size:85%">The previous information was derived from ClinicalTrials.gov on 09/ | <span style="font-size:85%">The previous information was derived from ClinicalTrials.gov on 09/25/2013 using the identification number NCT00266045.</span> | ||
==Eligibility Criteria== | ==Eligibility Criteria== | ||
Latest revision as of 19:13, 25 September 2013
|
D-Dimer Microchapters |
|
Clinical Correlation |
|---|
|
Clinical Trials |
|
PROLONG-II Study On the Web |
|
American Roentgen Ray Society Images of PROLONG-II Study |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Official Title
A Multicentre, Prospective, Observational Study on the Predictive Role for Recurrence of D-dimer Levels Measured During and After Anticoagulation in Patients With a First Venous Thromboembolism Episode (the PROLONG-II Study)
Objective
The Prolong-Two study aims at assessing the predictive role for recurrence of D-dimer levels measured: a) during anticoagulation, b) one month after its withdrawal and c) periodically during follow up
Sponsor
St. Orsola Hospital
Timeline
| Timeline | |
| Start Date | August 2005 |
| End Date | June 2008 |
| Status | Completed |
The previous information was derived from ClinicalTrials.gov on 09/25/2013 using the identification number NCT00266045
Study Description
| Study Description | |
| Study Type | Observational |
| Study Design | Observational Model: Cohort Time Perspective: Prospective |
| Study Details | |
| Condition | Deep Vein Thrombosis Pulmonary Embolism |
| Population Size | 355 |
The previous information was derived from ClinicalTrials.gov on 09/25/2013 using the identification number NCT00266045.
Eligibility Criteria
Inclusion Criteria
- Age > 18 years
- After a first documented idiopathic proximal deep vein thrombosis and/or pulmonary embolism
- After at least 6 months of oral anticoagulation
- After written informed consent
Exclusion Criteria
- Age > 82 y
- Recurrent venous thromboembolism
- If the Venous thromboembolism occurred:
- during pregnancy or puerperium
- after recent (i.e. within three months) fracture or plaster casting of a leg,
- after immobilization with confinement to bed for three consecutive days after surgery with general anesthesia lasting longer than 30 minutes
- Patients with:
- active cancer
- antiphospholipid antibody syndrome
- antithrombin deficiency
- serious liver disease or renal insufficiency (creatininemia > 2 mg/dL),
- other indications for anticoagulation or contraindications for this treatment
- limited life expectation
- Patients who live too far from the clinical center